Hyperlipidemia ICD-10 Codes: E78.5, E78.2, E78.00 and the FY2027 Code List

E78.5 is the billable ICD-10-CM code for hyperlipidemia, unspecified, active for FY2027 under category E78, disorders of lipoprotein metabolism and other lipidemias. It is also one of the most overused diagnosis codes in primary care and cardiology billing. Coders reach for it by default, even when the chart clearly supports mixed hyperlipidemia (E78.2), pure hypercholesterolemia (E78.00), or one of the familial hypercholesterolemia codes added in FY2026 (E78.010, E78.011, E78.019)

That default habit has a price. It invites payer reviews, weakens audit defensibility, understates risk for Medicare Advantage patients, and in busy practices it creates denial patterns that repeat every month.

This guide from MZ Medical Billing walks through the full E78 code family, the FY2026 and FY2027 updates, CPT pairings, sequencing with diabetes and heart disease, Z-codes, HCC documentation, and the denial patterns MZ’s billing team sees most often on lipid claims.

Hyperlipidemia ICD-10 Code List for FY2027

The E78 category holds header codes and billable subcodes. Only billable codes can go on a claim, and coding to the most specific billable code is both a clean claim requirement and a way to protect reimbursement.

Three codes in this list are headers: E78.0, E78.01, and E78.4. Sending any of them on a claim produces an automatic rejection. The note on E78.5 is a documentation signal, not a ban. E78.5 is correct when the chart does not support anything more specific. The trouble starts when it is used even though the chart does.

Coding lipid disorders to full specificity affects three things at once: clean claim rates, audit defensibility, and HCC risk accuracy for Medicare Advantage panels. FY2026 brought the biggest change to this code family in years, mostly in the familial hypercholesterolemia branch. FY2027 made no changes to the E78 family.

What Hyperlipidemia Means for Coding and Billing

Hyperlipidemia is an elevated level of lipids in the blood, meaning cholesterol, triglycerides, or both. It raises cardiovascular risk by contributing to atherosclerosis and, over time, coronary artery disease. In ICD-10-CM it sits in the endocrine and metabolic chapter as a disorder of lipoprotein metabolism.

Three lab values drive most lipid coding decisions:

• LDL cholesterol, the low-density lipoprotein that drives plaque buildup.
• HDL cholesterol, the high-density lipoprotein that protects the arteries.
• Triglycerides, blood fats that raise cardiovascular risk and, when very high, pancreatitis risk.

A standard lipid panel measures all three. Most patients have no symptoms, which is why screening encounters coded to Z13.220 are common before any diagnosis exists.

From a billing point of view, the diagnosis itself is not hard. The difficulty is in choosing the right code. That choice depends on which lipids are elevated, how high they are, whether a familial pattern is documented, and whether diabetes or heart disease changes the sequencing. None of that is inside the code. All of it lives in the chart. That is the work our medical coding service does on every claim.

The volume makes this matter. CDC data shows roughly 86 million US adults have total cholesterol above 200 mg/dL, so lipid claims are among the highest-volume encounters in primary care and cardiology. When the same small coding gap repeats across thousands of claims, the revenue leak becomes substantial over a year. MZ Medical Billing sees this pattern regularly when reviewing lipid claims for new clients.

Hyperlipidemia vs Dyslipidemia: The Coding Difference

Coders mix these two terms up every day, and payers care because the documentation needs and the resulting codes can differ.

Hyperlipidemia is a subset of dyslipidemia. Every case of hyperlipidemia is dyslipidemia, but not every case of dyslipidemia is hyperlipidemia. A patient with low HDL and normal LDL has dyslipidemia without hyperlipidemia. A patient with elevated LDL has both.

When documentation is thin, both terms often land on E78.5, and that is where revenue starts slipping. Proper documentation usually supports E78.00 for pure cholesterol elevation, E78.1 for pure triglyceride elevation, E78.2 for mixed elevation, or E78.6 for low HDL. Each of these is more specific, easier to defend on audit, and more useful for risk adjustment.

Patient-facing language creates a steady documentation gap. When the chart says “high cholesterol,” the coder still needs lab values to decide between E78.00 and E78.5. The assessment is a starting point. The lab results in the same note usually finish the decision.

Hyperlipidemia and high cholesterol are also not the same thing. High cholesterol means elevated LDL or total cholesterol. Hyperlipidemia is the broader term covering elevated cholesterol, elevated triglycerides, or both. Well-documented high cholesterol with normal triglycerides codes to E78.00. Elevation of both codes to E78.2.

E78.5 Hyperlipidemia, Unspecified: When It Fits and When It Costs You

E78.5 is billable, active for FY2027, and crosswalks to ICD-9 code 272.4, other and unspecified hyperlipidemia. It is correct when documentation does not support a more specific lipid disorder. It is also the most overused code in the E78 family, and payers know it. E78.5 overuse shows up regularly in denial pattern audits across payer types.

When E78.5 Is the Right Choice

Three situations genuinely support E78.5:

• Screening visit before labs return. A patient comes in for a wellness visit, labs are ordered, and results are not back. The chart notes suspected hyperlipidemia. With no documented lipid type on the date of service, E78.5 is defensible. The code can be updated once results arrive.
• Referral with unspecified elevated lipids. A patient is referred to cardiology with “elevated lipids” and no lab values or lipid type available at the visit. E78.5 is the defensible choice.
• Assessment with no characterization at all. The note says “hyperlipidemia” with no lab values and no further description. E78.5 applies, and this is also the moment to query the provider.

When E78.5 Leads to Denials

Four patterns produce most E78.5 denials and most of the lost revenue:

1. Mixed elevation coded as E78.5 instead of E78.2. The chart shows LDL at 162 mg/dL and triglycerides at 240 mg/dL. The assessment says “hyperlipidemia.” The claim goes out as E78.5. It may pay at first, but post-payment review finds the mismatch between the labs and the code. When both are elevated, the correct code is E78.2.
2. Familial hypercholesterolemia coded as E78.5. Since October 1, 2025, E78.01 has three billable subcodes. Practices that have not updated their code sets keep coding documented familial cases to E78.5 or the old E78.01 header. The correct codes are E78.010, E78.011, or E78.019.
3. Diabetic dyslipidemia coded as E78.5 alone. When the provider links the lipid disorder to Type 2 diabetes, the correct sequence is E11.69 followed by the specific E78 code. E78.5 alone misses both the sequencing and the specificity.
4. Lipid screening coded as E78.5 instead of Z13.220. An asymptomatic patient with no lipid diagnosis gets a routine lipid panel. The correct code is Z13.220. Using E78.5 turns a preventive encounter into a diagnostic one and triggers preventive benefit denials.

Each of these comes from a documentation gap, an outdated template, or a workflow shortcut rather than a lack of coding knowledge. That is good news, because workflow problems are fixable. When MZ Medical Billing takes over lipid-heavy accounts, correcting these four patterns is usually one of the first improvements clients see on their remittances.

E78.2 Mixed Hyperlipidemia: The Specificity Upgrade

E78.2 applies when both elevated cholesterol and elevated triglycerides are documented. It corresponds to Fredrickson Type IIb and Type III hyperlipoproteinemia under the National Lipid Association classification. Payers prefer it over E78.5 when the chart supports both elevations, and it is the most under-coded specific code in the family.

When E78.2 Applies

Both elevations must be supported. Under NCEP ATP III criteria, the general thresholds are LDL above 130 mg/dL and triglycerides above 150 mg/dL. A lipid panel showing both, plus a provider assessment naming the condition, supports E78.2.

Example: total cholesterol 240 mg/dL, LDL 165 mg/dL, triglycerides 220 mg/dL. Assessment: “mixed hyperlipidemia, starting statin therapy.” That is a clean E78.2 claim.

The tabular list for E78.2 also covers older terms that still appear in charts: broad-beta lipoproteinemia, combined hyperlipidemia not otherwise specified, floating-beta lipoproteinemia, and hypercholesterolemia with endogenous hyperglyceridemia. Any of these terms supports E78.2 even when the provider never wrote “mixed hyperlipidemia.”

Do Not Stack E78.2 With E78.00

This is the most common stacking error in the family. Some coders assign E78.2 for the triglycerides and E78.00 for the cholesterol, believing each captures a separate finding. It does not work that way. E78.2 already includes the cholesterol component. Adding E78.00 duplicates the same finding, triggers payer edits, and suggests two lipid disorders when there is only one.

E78.2 alone captures both elevations. Add E11.69 when diabetes is linked, I10 for hypertension, or I25.10 for coronary artery disease as the record supports. Never report two E78 codes for the same lipid finding.

E78.00 Pure Hypercholesterolemia and the E78.0 Header Trap

E78.0 is a non-billable header. The billable code is E78.00, pure hypercholesterolemia, unspecified, which crosswalks to ICD-9 code 272.0. Sending E78.0 on a claim results in automatic rejection.

E78.00 applies when total cholesterol or LDL is elevated while triglycerides stay normal. Under NCEP ATP III criteria referenced in AHA/ACC cholesterol guidelines, that means LDL above 130 mg/dL with triglycerides below 150 mg/dL.

The difference from E78.5 is documentation. E78.5 fits when the chart cannot name the lipid type. E78.00 fits when the chart confirms high cholesterol with normal triglycerides. The provider does not need to write “pure hypercholesterolemia” word for word. The lab values and the assessment together support the code.

What the Chart Needs for E78.00

• Elevated LDL or total cholesterol visible in the note, order, or attached result. Total cholesterol above 200 mg/dL or LDL above 130 mg/dL meets the threshold.
• Normal triglycerides documented. This is the element coders miss most often. If triglycerides are elevated, E78.00 no longer applies and E78.2 does.
• An assessment naming the disorder, such as “elevated LDL,” “pure hypercholesterolemia,” or “high cholesterol with normal triglycerides.”

A note that supports E78.00: “Lipid panel reviewed. Total cholesterol 248 mg/dL, LDL 170 mg/dL, HDL 52 mg/dL, triglycerides 98 mg/dL. Assessment: elevated LDL, starting atorvastatin 20 mg.”

A note that forces E78.5: “Assessment: high cholesterol. Plan: start statin, follow up in 3 months.” No labs, no triglyceride status. The issue here is documentation quality, not coder skill.

Familial Hypercholesterolemia Codes Added in FY2026: E78.010, E78.011, and E78.019

Effective October 1, 2025, and unchanged in FY2027 (effective October 1, 2026), E78.01 was expanded from a single parent code into three billable subcodes. This is the most clinically meaningful change to lipid coding in years, and many practices still have not updated their EHR templates, superbills, or coder reference sheets.

E78.010: Homozygous Familial Hypercholesterolemia

HoFH produces earlier and more severe cardiovascular disease than any other lipid disorder. Treatment usually starts with high-intensity statins and often adds PCSK9 inhibitors such as evolocumab or alirocumab, bempedoic acid, or LDL apheresis.

Documentation should include genetic testing confirming a homozygous mutation, family history of premature cardiovascular disease, and LDL-C that stays above target despite maximum tolerated therapy. Because HoFH is rare and the drugs are costly, prior authorizations increasingly require E78.010 specifically rather than the old E78.01.

E78.011: Heterozygous Familial Hypercholesterolemia

HeFH is far more common and shows up regularly in both cardiology and primary care panels. Statins are first-line, and patients who do not reach target on statins alone often qualify for PCSK9 inhibitors when documentation supports it.

Documentation should include genetic testing or Dutch Lipid Clinic Network scoring, family history of early cardiovascular disease, and persistently elevated LDL. Accurate HeFH coding also supports risk accuracy for Medicare Advantage patients, since risk scoring reflects the full clinical picture.

E78.019: Familial Hypercholesterolemia, Unspecified

Use E78.019 only when familial hypercholesterolemia is documented but the type is not yet known. For example: “Family history of high cholesterol, suspected familial hypercholesterolemia, genetic testing ordered.” Once results return, update to E78.010 or E78.011.

Payer scrutiny on unspecified familial codes has grown since the expansion. MZ Medical Billing recommends replacing every E78.01 entry in EHR favorites and superbills with the three new subcodes, then running a quarterly review of any claims still carrying the old code.

E78.1 and E78.3: Coding Elevated Triglycerides and Hyperchylomicronemia

Triglyceride disorders split into two codes that are easy to confuse: E78.1 for pure hyperglyceridemia and E78.3 for the more severe hyperchylomicronemia.

E78.1 Pure Hyperglyceridemia

E78.1 applies when triglycerides are elevated and cholesterol is normal or near normal. It crosswalks to ICD-9 code 272.1. Under NCEP ATP III, triglycerides above 150 mg/dL are borderline high, and above 500 mg/dL pancreatitis risk climbs sharply.

Secondary causes should be coded separately when the provider documents them, since each is its own clinical problem:

• Poorly controlled Type 2 diabetes, such as E11.65 for Type 2 diabetes with hyperglycemia, or E11.69 when the provider links the lipid disorder to diabetes.
• Alcohol use disorders coded in the F10 range.
• Medication effects from corticosteroids, thiazide diuretics, or certain retinoids.

Severe hypertriglyceridemia above 500 mg/dL often moves to fibrates such as fenofibrate or gemfibrozil, or prescription omega-3 fatty acids. The note should reflect the pancreatitis risk assessment, treatment plan, and monitoring plan.

Choosing Between E78.1 and E78.2

The rule is simple. If triglycerides and cholesterol are both elevated, code E78.2. If only triglycerides are elevated, code E78.1.

The usual trap: the assessment says “high triglycerides,” the coder picks E78.1, and nobody checks the full panel. If LDL or total cholesterol is also elevated, E78.2 is correct regardless of the shorthand in the assessment. When the labs and the assessment do not match, query the provider or code to what the labs clearly support, provided the assessment does not contradict it.

Patients on icosapent ethyl or other prescription omega-3 products often need specific E78.1 documentation for prior authorization, usually alongside the supporting lab values. MZ Medical Billing’s prior authorization team handles these lipid specialty drug approvals, where documentation specificity often decides the outcome.

E78.3 Hyperchylomicronemia

E78.3 covers elevated chylomicrons, typically with triglycerides above 1,000 mg/dL. It corresponds to Fredrickson Type I and Type V and crosswalks to ICD-9 code 272.3.

It carries serious pancreatitis risk and a recognizable clinical picture: abdominal pain from pancreatic inflammation, eruptive xanthomas, and lipemia retinalis on eye exam. Causes include lipoprotein lipase deficiency, apolipoprotein C-II deficiency, and severe secondary hypertriglyceridemia from uncontrolled diabetes or heavy alcohol use.

The chart should document chylomicron elevation, triglycerides above 1,000 mg/dL, or the clinical signs above. When acute pancreatitis drives the visit, the K85 code for acute pancreatitis usually comes first, with E78.3 following as the underlying condition. Treatment often includes strict dietary fat restriction, fibrates, and omega-3 fatty acids.

E78.3 reflects a higher-acuity patient than E78.1. Specialty drugs such as volanesorsen for familial chylomicronemia syndrome require E78.3 documentation specifically, so defaulting to E78.1 or E78.5 for these patients costs both accuracy and reimbursement.

E78.41 and E78.49: Lipoprotein(a) and Other Hyperlipidemia

E78.4 is a non-billable header. Its two billable subcodes are E78.41 for elevated lipoprotein(a) and E78.49 for other hyperlipidemia.

E78.41 Elevated Lipoprotein(a)

Lipoprotein(a) is a genetically determined particle that raises both cardiovascular and aortic stenosis risk independently of standard lipid measures. Under AHA/ACC guidelines it is clinically significant above 50 mg/dL, roughly 125 nmol/L.

A routine lipid panel does not measure it. The provider has to order a separate Lp(a) assay, CPT 83695. Without that order and result, E78.41 cannot be coded.

Documentation should show the elevated result and an assessment naming it as a risk factor, such as “elevated Lp(a), independent cardiovascular risk factor.”

Example: a cardiology patient has LDL of 112 mg/dL but a strong family history of early coronary disease. The cardiologist orders an Lp(a) test, which returns at 90 mg/dL. The assessment names the elevation as a risk factor. This is an E78.41 claim, not E78.5.

Several Lp(a)-targeted therapies, including lepodisiran and pelacarsen, are in late-stage trials. Once approved, prior authorization will almost certainly require E78.41. Practices that code it accurately now will be ready.

E78.49 Other Hyperlipidemia

E78.49 covers documented lipid disorders that do not fit E78.0 through E78.41. Common uses include familial combined hyperlipidemia not described by a more specific code, drug-induced hyperlipidemia from retinoids or corticosteroids, and hyperlipidemia secondary to conditions such as nephrotic syndrome or hypothyroidism.

The chart must name the specific disorder. Vague language defaults to E78.5, not E78.49. Familial combined hyperlipidemia causes the most confusion here. When the chart describes a familial pattern with family history but no confirmed receptor mutation, E78.49 may be more accurate than E78.2 even when both lipids are elevated.

Sequencing Hyperlipidemia With Diabetes, Hypertension, and CAD

Under ICD-10-CM Official Guidelines Section I.C.4, the condition driving the encounter generally leads. The rules look straightforward, but sequencing errors on these combinations are among the top reasons lipid claims are denied or downcoded.

Diabetes and Hyperlipidemia

When the provider documents a causal link, such as “hyperlipidemia due to diabetes,” E11.69 leads, followed by the specific lipid code. Mixed elevation means E78.2 follows. LDL elevation alone means E78.00 follows.

When no link is documented, code both separately and sequence by the reason for the visit. The most common mistake is coding E78.5 because the visit was framed around diabetes, even though the chart clearly shows mixed elevation. The visit focus changes the order, not the specificity.

Hypertension and Hyperlipidemia

These two conditions are not treated as causally linked under ICD-10-CM. Code both and sequence by encounter focus. A frequent error is always putting I10 first because hypertension feels more serious. The guideline is based on encounter focus, not perceived severity. If the note does not make the focus clear, query the provider.

Coronary Artery Disease and Hyperlipidemia

A visit about chest pain, post-MI care, or cardiac recovery leads with I25.10. A visit about statin adjustment or a follow-up lipid panel leads with the E78 code. When the assessment states lipid management for ASCVD risk reduction, the lipid code is the natural focus.

Both conditions contribute to risk under CMS-HCC v28 when properly documented, so accurate sequencing helps the risk model recognize each one. MZ Medical Billing reviews these comorbidity combinations on aging reports and traces repeat denials back to the documentation gaps behind them.

Z-Codes for Screening, Family History, and Long-Term Therapy

Z-codes capture screening, history, and status. Using them incorrectly costs money two ways: preventive services coded as diagnostic lose preventive coverage, and diagnostic services coded as screening lose medical necessity support.

Z13.220 Lipid Screening

Z13.220 applies only when the visit is purely preventive, the patient has no symptoms, and there is no documented lipid disorder. Medicare covers cardiovascular screening blood tests once every five years for asymptomatic beneficiaries, and many commercial plans cover lipid screening as a preventive benefit with no cost sharing.

Once hyperlipidemia is diagnosed, every later lipid panel is diagnostic monitoring. Coding Z13.220 on an established patient triggers preventive benefit denials and undermines the medical necessity of the test.

Z83.42 Family History

Z83.42 supports the active diagnosis rather than replacing it. A patient with E78.00 and a documented family history of premature coronary disease is coded with both. It also helps justify more aggressive testing, earlier statin start, or Lp(a) testing when the patient’s own numbers are borderline.

Z79.899 Long-Term Drug Therapy

There is no statin-specific long-term therapy code, so ongoing statin use is captured with Z79.899, other long term (current) drug therapy. It always accompanies the active E78 code. A patient with E78.2 who has been on atorvastatin for three years and comes in for a lipid panel and refill is coded E78.2 plus Z79.899. It adds context that supports monitoring frequency when payers question it.

CPT Codes That Pair With E78 Diagnoses

The ICD-10 code explains why. The CPT code explains what was done. On lipid claims, mismatched pairings are easy for payer edits to catch because the lab result and the diagnosis sit on the same claim.

CPT 80061 Lipid Panel

80061 is the most billed CPT code for lipid disorders and the most common source of CPT-ICD pairing denials. For monitoring an established patient, pair it with the active E78 code. For screening an asymptomatic patient, pair it with Z13.220.

The typical mistake is billing 80061 with E78.5 when the results on that same claim show mixed elevation or pure cholesterol elevation. When the result shows LDL 160 and triglycerides 240 but the diagnosis is unspecified, the mismatch invites review. The results and the code should tell the same story.

Individual Component Codes

● 82465, total cholesterol, appears occasionally in screening when only total cholesterol is ordered.

● 83718, HDL, pairs with E78.6 when isolated low HDL is the concern.

● 83721, direct LDL, matters most when triglycerides exceed 400 mg/dL. At that level the Friedewald calculation becomes unreliable, so providers order a direct LDL measurement instead.

● 84478, triglycerides alone, appears in monitoring for E78.1 or E78.3 patients between full panels.

● 83695, Lp(a), pairs with E78.41 and will see more volume as Lp(a) therapies approach approval.

Accurate pairing supports both medical necessity and clean payment. MZ Medical Billing’s revenue cycle team maps pairing denials by payer and fixes the workflow that produces them, rather than working the same denial again every month.

HCC Risk Adjustment and MEAT Documentation

Under CMS-HCC v28, the Medicare Advantage risk model for payment year 2026, most uncomplicated lipid codes, including E78.00, E78.1, E78.2, and E78.5, do not map to an HCC category on their own. That does not make specificity unimportant.

Risk scores reflect the whole clinical picture. A patient with documented HeFH (E78.011), coronary artery disease (I25.10), and diabetes with a linked complication (E11.69) has three

accurately captured conditions. Coding the same patient with E78.5 in place of E78.011 understates the clinical picture, even though the heart and diabetes codes are present. Across a Medicare Advantage panel, those understatements add up.

MEAT Criteria for Lipid Diagnoses

Auditors use MEAT to confirm that each diagnosis on a claim was actually addressed during the visit.

A note with all four elements supports E78.2 and holds up on post-payment review. A note that lists “hyperlipidemia” in the problem list with no monitoring, evaluation, or plan is at risk of downcoding or recoupment. Practices in value-based contracts or with large Medicare Advantage panels benefit from building MEAT prompts into their lipid encounter templates, something MZ Medical Billing helps clients set up as part of documentation reviews.

Coding Errors and Denial Codes on Lipid Claims

After reviewing large volumes of lipid claims across specialties and payers, the same five coding errors and four denial codes appear again and again.

The Five Most Common Coding Errors

Every one of these comes from documentation habits, template lag, or default workflows. None requires advanced coding knowledge to fix, and most need only a one-time template update.

The Four Denial Codes That Keep Coming Back

CO-11 Diagnosis and Procedure Mismatch

CO-11 is the most common lipid denial. A lipid panel billed with Z00.00 tells the payer there were no abnormal findings and gives no reason for the test. Use the active E78 code for monitoring, Z13.220 for true screening, and confirm the diagnosis appears on the payer’s covered list for that CPT code.

CO-50 Medical Necessity

CO-50 usually hits frequent testing on stable patients. Many payers allow quarterly panels during dose adjustment but limit testing once the patient is stable. When testing happens sooner, the chart must explain why, such as a recent statin change or an abnormal prior result.

CO-16 Missing or Invalid Information

On lipid claims, CO-16 often fires when E78.5 is valid but falls short of a payer’s specificity rule for a higher-cost or higher-frequency test. It is a workflow and edit configuration problem, not a knowledge problem.

N115 Documentation Not Established

N115 shows up on appeals that include only the lab result. Appeals succeed when they include the full note showing the assessment, monitoring rationale, treatment plan, and clinical context. MZ Medical Billing’s denial management team builds appeal templates that pull all of this together automatically, and tracks lipid denials by payer so the front-end cause gets fixed once.

Frequently Asked Questions About Hyperlipidemia ICD-10 Coding

What is the ICD-10 code for hyperlipidemia?

The general code is E78.5, hyperlipidemia, unspecified, billable for FY2027 under category E78. When the chart supports a specific type, use E78.00 for pure hypercholesterolemia, E78.1 for pure hyperglyceridemia, or E78.2 for mixed hyperlipidemia instead.

Is hyperlipidemia the same as high cholesterol?

Not exactly. High cholesterol means elevated LDL or total cholesterol. Hyperlipidemia covers elevated cholesterol, elevated triglycerides, or both. Well-documented high cholesterol alone codes to E78.00, and elevation of both codes to E78.2.

What is the difference between E78.5 and E78.2?

E78.5 is used when the lipid type is not documented. E78.2 is used when both cholesterol and triglycerides are elevated. When the panel shows both, E78.2 is the correct and payer-preferred choice.

What changed in hyperlipidemia coding for FY2026 and FY2027?

E78.01 was expanded into E78.010 for homozygous, E78.011 for heterozygous, and E78.019 for unspecified familial hypercholesterolemia, effective October 1, 2025 and active through September 30, 2026.

What CPT code pairs with a hyperlipidemia diagnosis?

CPT 80061, the lipid panel, is the most common pairing. Others include 83721 for direct LDL, 84478 for triglycerides, and 83695 for lipoprotein(a), which pairs with E78.41.

How do you code diabetes with hyperlipidemia?

When the provider links them, code E11.69 first, followed by the specific E78 code. When no link is documented, code both and sequence by the reason for the visit, following ICD-10-CM Guidelines Section I.C.4.

When should Z13.220 be used instead of E78.5?

Only for asymptomatic patients with no lipid diagnosis during a preventive visit. Once hyperlipidemia is diagnosed, later lipid panels are diagnostic and use the active E78 code.

Is hyperlipidemia considered heart disease?

No. It is a cardiovascular risk factor classified with endocrine and metabolic disorders. Related conditions such as coronary artery disease, heart attack, and stroke are coded separately when documented.

What is the ICD-9 equivalent of E78.5?

E78.5 crosswalks to ICD-9 code 272.4, other and unspecified hyperlipidemia. The wider E78 family maps to the 272 range, with more detail available under ICD-10.

How often should hyperlipidemia be screened?

AHA/ACC guidelines recommend a lipid panel every four to six years for adults 20 and older without risk factors. Patients with risk factors, family history of early heart disease, or an existing diagnosis are monitored more often based on treatment and payer rules.

Hyperlipidemia coding looks simple until the same denials start coming back. The codes themselves are stable. The workflows around them are where claims get downcoded, delayed, or returned. If your team keeps seeing E78.5 defaults, CO-11 and CO-50 denials, or missed familial hypercholesterolemia codes, MZ Medical Billing can review your lipid claims, fix the upstream documentation and template gaps, and keep these claims clean from the first submission.